Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Sunesis Pharmaceutic (SNSS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 49,261
  • Shares Outstanding, K 72,528
  • Annual Sales, $ 240 K
  • Annual Income, $ -26,620 K
  • 60-Month Beta 2.98
  • Price/Sales 214.22
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.64
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/06/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.10
  • Number of Estimates 3
  • High Estimate -0.08
  • Low Estimate -0.11
  • Prior Year -0.20
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.57 +19.30%
on 06/12/19
1.19 -42.86%
on 05/21/19
-0.46 (-40.35%)
since 05/20/19
3-Month
0.57 +19.30%
on 06/12/19
1.77 -61.58%
on 04/04/19
-0.24 (-26.09%)
since 03/20/19
52-Week
0.20 +240.00%
on 12/21/18
2.60 -73.85%
on 08/07/18
-1.59 (-70.04%)
since 06/20/18

Most Recent Stories

More News
Sunesis: 1Q Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. (AP) _ Sunesis Pharmaceuticals Inc. (SNSS) on Wednesday reported a loss of $5.9 million in its first quarter.

SNSS : 0.67 (-1.47%)
Sunesis Pharmaceuticals Reports First Quarter 2019 Financial Results and Recent Highlights

Phase 1b/2 Trial of Vecabrutinib Advances into 200 mg Cohort

SNSS : 0.67 (-1.47%)
What's in the Cards for Sunesis (SNSS) This Earnings Season?

Sunesis Pharmaceuticals' (SNSS) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, vecabrutinib.

GILD : 68.39 (+0.19%)
SNSS : 0.67 (-1.47%)
BIIB : 235.32 (+0.61%)
TAK : 17.77 (-0.28%)
Sunesis Pharmaceuticals to Host Conference Call on May 8th to Discuss First Quarter 2019 Financial Results and Recent Highlights

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Wednesday, May 8, 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for...

SNSS : 0.67 (-1.47%)
Sunesis Pharmaceuticals Announces Refinancing of Existing Loan with $5.5 Million Loan from Silicon Valley Bank

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has entered into a $5.5 million loan agreement with Silicon Valley Bank. The new agreement allows the company to retire its existing...

SNSS : 0.67 (-1.47%)
Biotechs Strive to Provide Patients With More Affordable Treatment Options

The American Cancer Society estimated that in 1991, cancer deaths peaked at 215 deaths per 100,000 persons. As of 2014, the rate dropped significantly to just 161 deaths per 100,000 persons, representing...

AGEN : 2.95 (unch)
OMED : 0.93 (+4.49%)
ATOS : 2.08 (-3.70%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0103 (+63.49%)
SNSS : 0.67 (-1.47%)
Investor Expectations to Drive Momentum within Avalara, Sunesis Pharmaceuticals, NexPoint Residential Trust, Ferroglobe, China Online Education Group, and S&W Seed -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Avalara, Inc. (NYSE:AVLR), Sunesis...

GSM : 1.60 (unch)
SANW : 2.66 (-0.37%)
AVLR : 73.95 (+1.76%)
NXRT : 40.72 (+0.97%)
COE : 6.52 (-1.66%)
SNSS : 0.67 (-1.47%)
Biotech Firms Strive to Combat the Growing Burden of Diseases With Innovative Technologies

NEW YORK, April 4, 2019 The global burden of diseases continues to grow each year, despite various ongoing medical advancements. In 2017, the Institute for Health Metrics and Evaluation (IHME) said in...

SRNE : 3.88 (+5.72%)
ARQL : 10.18 (+5.17%)
ONCS : 2.76 (+1.10%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0103 (+63.49%)
SNSS : 0.67 (-1.47%)
Sunesis Pharmaceuticals to Present at 18th Annual Needham & Company Healthcare Conference

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the Needham...

SNSS : 0.67 (-1.47%)
The Zacks Analyst Blog Highlights: Roche, Celgene, Johnson and Johnson, Bayer and Sunesis Pharmaceuticals

The Zacks Analyst Blog Highlights: Roche, Celgene, Johnson and Johnson, Bayer and Sunesis Pharmaceuticals

BAYRY : 15.6150 (+1.00%)
CELG : 98.11 (+0.29%)
JNJ : 142.04 (+1.13%)
RHHBY : 35.7300 (+1.42%)
SNSS : 0.67 (-1.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

See More Share

Trade SNSS with:

Business Summary

Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing...

See More

Key Turning Points

2nd Resistance Point 0.76
1st Resistance Point 0.72
Last Price 0.67
1st Support Level 0.65
2nd Support Level 0.62

See More

52-Week High 2.60
Fibonacci 61.8% 1.68
Fibonacci 50% 1.40
Fibonacci 38.2% 1.12
Last Price 0.67
52-Week Low 0.20

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar